SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Doug Bean who wrote (1427)9/28/1999 7:12:00 AM
From: Andy Blaher  Read Replies (1) | Respond to of 1837
 
I really didn't expect to see very good numbers this year anyway. I just didn't expect the impact the last qtr losses had and I agree that some red ink next qtr will only make it worse. However, I think some good news, such as approval for long term symptoms particularly if it comes after the next red ink could turn this stock around for good. The only question I am pondering now is when to increase my position. Without good news and with another red qtr I wouldn't be surprised to see us back around 5 before the end of the year.



To: Doug Bean who wrote (1427)10/5/1999 10:34:00 AM
From: Firenze  Read Replies (1) | Respond to of 1837
 
Post,
Can any of you pharmacists tell me if Cenestin is being fully reimbursed by the major PBMs and MCOs? I hear that Premarin is still the preferred drug on most formularies and that Cenestin actually has a higher copayment than Premarin.

If this is the case, how does this information shape up.
Firenze


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News